Tag: development

Beauty meets intelligent tech: L'Oréal Turkey unlocks faster, more consistent creative production with AdCreative.ai ISTANBUL and PARIS, July 23, 2025 /PRNewswire/ -- L'Oréal Turkey has partnered with...

ROTTERDAM, Netherlands, July 23, 2025 /PRNewswire/ -- In a groundbreaking development for the global marine fuels industry, leading shipping and bunkering companies have come...

Recorded Q2'25 consolidated revenue of KRW 1,289.9 billionRecorded Q2'25 consolidated operating profit of KRW 475.6 billionSolid momentum sustained through capacity ramp-up and stable project...

KOLKATA, India, July 23, 2025 /PRNewswire/ -- Himadri Speciality Chemical Ltd, a global frontrunner in advanced materials and sustainable chemical solutions, has been named...

Empowering the Next Generation of Hotel and Culinary Professionals SACRAMENTO, Calif., July 23, 2025 /PRNewswire/ -- Ninety-seven students pursuing degrees in hotel management, tourism and...

NEW DELHI, July 23, 2025 /PRNewswire/ -- TACC Limited is pleased to announce the signing of a Memorandum of Understanding (MoU) with National Council...

CEO Dr. Michael Fübi's visit reinforces India's growing role in shaping global compliance standards, sustainable industries, and future-ready workforce development. BANGALORE, India, July 23,...

BERLIN, July 23, 2025 /PRNewswire/ -- Growatt, a world-leading provider of distributed solar and energy storage solutions (ESS), has secured top positions in the...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

SINGAPORE, July 23, 2025 /PRNewswire/ -- On 17 July 2025, Giti Tire was honoured to be conferred as a 3 heart Company of Good at...

SINGAPORE, July 23, 2025 /PRNewswire/ -- Panduit Corp has been awarded the prestigious Asia Responsible Enterprise Award (AREA) 2025 under the Social Empowerment category...